| Title: |
Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis |
| Authors: |
Maglione, Alessandro; Francese, Rachele; Arduino, Irene; Rosso, Rachele; Matta, Manuela; Rolla, Simona; Lembo, David; Clerico, Marinella |
| Contributors: |
Maglione, Alessandro; Francese, Rachele; Arduino, Irene; Rosso, Rachele; Matta, Manuela; Rolla, Simona; Lembo, David; Clerico, Marinella |
| Publication Year: |
2023 |
| Collection: |
Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto) |
| Subject Terms: |
COVID-19; T-cell response; anti-SARS-CoV-2 vaccination; disease modifying therapie; multiple sclerosi; neutralizing antibodies |
| Description: |
Background and objectivesLong lasting immune response to anti-SARS-CoV-2 vaccination in people with Multiple Sclerosis (pwMS) is still largely unexplored. Our study aimed at evaluating the persistence of the elicited amount of neutralizing antibodies (Ab), their activity and T cell response after three doses of anti-SARS-CoV-2 vaccine in pwMS. MethodsWe performed a prospective observational study in pwMS undergoing SARS-CoV-2 mRNA vaccinations. Anti-Region Binding Domain (anti-RBD) of the spike (S) protein immunoglobulin G (IgG) titers were measured by ELISA. The neutralization efficacy of collected sera was measured by SARS-CoV-2 pseudovirion-based neutralization assay. The frequency of Spike-specific IFN & gamma;-producing CD4+ and CD8+ T cells was measured by stimulating Peripheral Blood Mononuclear Cells (PBMCs) with a pool of peptides covering the complete protein coding sequence of the SARS-CoV-2 S. ResultsBlood samples from 70 pwMS (11 untreated pwMS, 11 under dimethyl fumarate, 9 under interferon-& gamma;, 6 under alemtuzumab, 8 under cladribine, 12 under fingolimod and 13 under ocrelizumab) and 24 healthy donors were collected before and up to six months after three vaccine doses. Overall, anti-SARS-CoV-2 mRNA vaccine elicited comparable levels of anti-RBD IgGs, neutralizing activity and anti-S T cell response both in untreated, treated pwMS and HD that last six months after vaccination. An exception was represented by ocrelizumab-treated pwMS that showed reduced levels of IgGs (p |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/37409134; info:eu-repo/semantics/altIdentifier/wos/WOS:001018665400001; volume:14; firstpage:1205879; lastpage:1205890; numberofpages:12; journal:FRONTIERS IN IMMUNOLOGY; https://hdl.handle.net/2318/1932150; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85163947453 |
| DOI: |
10.3389/fimmu.2023.1205879 |
| Availability: |
https://hdl.handle.net/2318/1932150; https://doi.org/10.3389/fimmu.2023.1205879 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.3EB50173 |
| Database: |
BASE |